Daily Newsletter

24 November 2023

Daily Newsletter

24 November 2023

Shalby signs amendment deal to build hospital in Mumbai, India

Following approval from the Charity Commissioner, the facility will be operational within an estimated two to three years.

November 24 2023

Shalby Multi-Speciality Hospitals, based in Ahmedabad, India, has enacted an amendment to the Operation and Management Agreement with The Santacruz Residents Association and Smt. Bhikhubai Chandulal Jalundwala General Hospital (BCJ) Trust.

This amendment grants the company the approval to proceed with the construction of a new hospital building in Santacruz, Mumbai, pending confirmation from the Charity Commissioner.

The project entails the establishment of a 175-bed hospital.

Under the amended agreement, the company will commit to an interest-free security deposit of Rs375m ($4.5m) to the trust, with Rs296.5m already disbursed.

The reimbursement of this deposit will span 30 years.

The trust will seek permission from the Charity Commissioner and, upon obtaining approval, the company will undertake the construction and management of the new hospital for a period of 30 years.

Should approval not be granted within 12 months, the trust is obligated to refund the security deposit, with a 9% interest rate.

The agreement delineates various terms, encompassing charitable responsibilities, the commercial operation date, licences and approvals, obligations of both the trust and the company, as well as the handling of existing and future liabilities.

Post approval, the facility is anticipated to be operational within an estimated two to three years.

Shalby operates 11 multispecialty tertiary hospitals and four orthopaedic centres under the Shalby Orthopedics Center of Excellence across India, boasting a total bed capacity exceeding 2,000 beds.

In addition, Shalby has ventured into the manufacture of knee and hip implants in the US.

Shalby has a team of more than 4,000 skilled doctors, surgeons, and support staff.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close